Personalized Synergistic Treatment System for Allergic Reactions
Legal Citation
Summary of the Inventive Concept
A novel system integrating hydrocortisone sodium phosphate, monothioglycerol, and cutting-edge technologies like AI, IoT, blockchain, and novel biocompatible materials to provide personalized treatment for allergic reactions.
Background and Problem Solved
The original patent disclosed an aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol, which has limitations in terms of dosage adjustment, treatment monitoring, and data security. The new inventive concept addresses these limitations by incorporating advanced technologies to create a more effective and personalized treatment system.
Detailed Description of the Inventive Concept
The system comprises a wearable device, a mobile application, and an AI-powered algorithm that administers a synergistic combination of hydrocortisone sodium phosphate and monothioglycerol to a subject. The mobile application monitors and adjusts the dosage based on the subject's vital signs and medical history. Additionally, the system can be integrated with IoT-enabled injection devices, blockchain technology, and novel biocompatible materials to enhance its functionality and security. The AI-driven diagnostic tool identifies the optimal dosage and administration route for the combination based on the subject's genetic profile and medical history.
Novelty and Inventive Step
The new claims introduce a synergistic combination of hydrocortisone sodium phosphate, monothioglycerol, and advanced technologies, which provides a non-obvious and novel solution to the problem of personalized treatment for allergic reactions. The integration of AI, IoT, blockchain, and novel biocompatible materials with the pharmaceutical formulation is a significant departure from the original patent and represents a substantial inventive step.
Alternative Embodiments and Variations
Alternative embodiments of the system could include different wearable devices, mobile applications, or AI algorithms. The system could also be adapted for use with other pharmaceutical formulations or treatment regimens. Additionally, the novel biocompatible material could be replaced with other advanced materials to enhance the system's performance.
Potential Commercial Applications and Market
The personalized synergistic treatment system has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of allergy treatment, immunology, and dermatology. The system's ability to provide personalized treatment and real-time monitoring could lead to improved treatment outcomes, increased patient satisfaction, and reduced healthcare costs.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical formulations, medical device technologies, and personalized medical treatment systems, with expertise in drug delivery, biotechnology, and digital health integration
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced degrees in pharmaceutical sciences, biomedical engineering, or related fields, possessing knowledge of drug formulation, medical device design, and emerging digital health technologies
Obviousness Rationale
A PHOSITA would recognize that integrating digital technologies with existing pharmaceutical formulations represents a predictable extension of current medical innovation trends. The combination of hydrocortisone sodium phosphate and monothioglycerol with AI, IoT, and personalized monitoring technologies follows established patterns of medical technology convergence. The technical elements proposed in the PTD are logical progressions of existing pharmaceutical and digital health approaches.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,555 |
|---|---|
| Title | Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol |
| Assignee(s) | Antares Pharma, Inc. |